EAU updates guidelines on screening, diagnosis, and management of localized prostate cancer

The European Association of Urology (EAU) has just updated its guideline document “EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent”. … READ MORE …

Provenge likely to be approved in Europe later this year

The European Medicines Agency’s Committee for Medicinal Products for Human Use today recommended that marketing authorization be approved for sipuleucel-T (Provenge) in the European Union. A final decision by the European Commission is likely later this year. … READ MORE …

European regulators approve enzalutamide for treatment of mCRPC

Yesterday, the European Commission approved the use of enzalutamide (Xtandi) for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) in men who have progressive disease after at least one cycle of docetaxel-based chemotherapy. … READ MORE …

Current issues related to management of advanced prostate cacner in Europe

According to an article on PharmaTimes Online, a new report issued in Europe suggests that "European healthcare systems are failing to deliver the latest medical breakthroughs to men with advanced prostate cancer." … READ MORE …

Zytiga approved in Europe for chemotherapy-naive mCRPC

As in the USA and some other countries, the European Union has now approved abiraterone acetate (Zytiga®), in combination with prednisone or prednisolone, for the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

CMPH recommends expanded indication for abiraterone in mCRPC … before chemotherapy

According to a summary statement of opinion issued yesterday by the Committee for Medicinal Products for Human Use (CMPH) of the European Mediciens Agency (EMEA), CMPH is recommending an expanded indication for the clinical use of abiraterone acetate in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

European Commission approves abiraterone acetate for mCRPC

Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July. … READ MORE …